0.4799
Jasper Therapeutics Inc stock is traded at $0.4799, with a volume of 242.01K.
It is down -9.81% in the last 24 hours and down -17.39% over the past month.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
See More
Previous Close:
$0.5321
Open:
$0.546
24h Volume:
242.01K
Relative Volume:
0.65
Market Cap:
$15.97M
Revenue:
Net Income/Loss:
$-55.73M
P/E Ratio:
-0.1487
EPS:
-3.2274
Net Cash Flow:
$-68.87M
1W Performance:
-15.84%
1M Performance:
-17.39%
6M Performance:
-50.32%
1Y Performance:
-80.65%
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Name
Jasper Therapeutics Inc
Sector
Industry
Phone
(650) 549-1400
Address
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
JSPR
Jasper Therapeutics Inc
|
0.4799 | 15.97M | 0 | -55.73M | -68.87M | -3.2274 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-26 | Resumed | William Blair | Outperform |
| Aug-12-26 | Initiated | Piper Sandler | Overweight |
| May-15-26 | Downgrade | TD Cowen | Buy → Hold |
| Mar-23-26 | Resumed | UBS | Neutral |
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Jul-08-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-07-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-13-25 | Initiated | UBS | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Sep-09-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-08-24 | Initiated | BTIG Research | Buy |
| Jun-27-24 | Initiated | Stifel | Buy |
| May-06-24 | Initiated | H.C. Wainwright | Buy |
| Apr-03-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-18-24 | Initiated | TD Cowen | Outperform |
| Aug-11-23 | Initiated | CapitalOne | Overweight |
| Feb-28-22 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Credit Suisse | Outperform |
| Oct-21-21 | Initiated | William Blair | Outperform |
| Oct-20-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-13-21 | Initiated | Oppenheimer | Outperform |
View All
Jasper Therapeutics Inc Stock (JSPR) Latest News
Jasper Therapeutics, Inc. (JSPR) stock price, news, quote and history - Yahoo Finance Singapore
All outstanding warrants are eligible for Jasper Therapeutics (JSPR)'s cash purchase offer. - Stock Titan
About $4 million is the expected payout if holders turn in all their rights to buy Jasper shares. - Stock Titan
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants - GlobeNewswire
Jasper Therapeutics approves reverse split for Jasper Therapeutics stock - AD HOC NEWS
Jasper Therapeutics Closes Kira Acquisition, $132M Financing; Pro Forma Cash $142.8M - Minichart
Stockholders give Jasper Therapeutics (JSPR) until December 31, 2026 to decide on a reverse split. - Stock Titan
After closing roughly $132M in financing, Jasper Therapeutics (JSPR) reports illustrative combined losses. - Stock Titan
Jasper Therapeutics Completes Kira Merger With $132 Million Private Placement - Minichart
Form 8K Jasper Therapeutics Inc For: 1 October By Investing.com - Investing.com Canada
Kira’s auditors cited going-concern doubt. Jasper Therapeutics (JSPR) adds its loss figures. - Stock Titan
Jasper Therapeutics announces CFO resignation and interim appointments - Investing.com
Jasper Therapeutics announces CFO resignation and interim appointments By Investing.com - Investing.com Nigeria
Form 8K Jasper Therapeutics Inc For: 28 September By Investing.com - Investing.com South Africa
Three interim appointments will follow the finance chief's departure at Jasper Therapeutics (JSPR). - Stock Titan
Jasper Therapeutics stock gains 4.05 percent as vote nears - AD HOC NEWS
Ten Jasper Therapeutics (JSPR) warrants are exercisable for one share as Nasdaq moves to remove their listing. - Stock Titan
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments - Taiwan News
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments - The Manila Times
Jasper Therapeutics Appoints Senior Vice President of Regulatory Affairs and Vice President of Clinical Development - Quiver Quantitative
A biotech company's New York talk will be webcast live - Stock Titan
Jasper Therapeutics (NASDAQ: JSPR) Schedules September 30 Vote on Increasing Authorized Common Stock - Kalkine Media
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Jasper Therapeutics Inc (JSPRW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Jasper Therapeutics Inc (JSPRW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Jasper Therapeutics (NASDAQ: JSPR) on clock after Nasdaq equity warning - Stock Titan
Jasper (JSPR) Latest: Gains 3.59% to Reach $0.72 in Latest Trading; Price Levels: Price Remains Between $0.68 Support and $0.76 Resistance under the Current SnapshotLong Setup Ideas - vinanet.vn
Wenru Song Net Worth (2026) - GuruFocus
Jasper Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Velan group shifts to passive stake in Jasper (NASDAQ: JSPR) - Stock Titan
Jasper Therapeutics beats Q2 expectations but shares fall after results - Yahoo Finance
Jasper Therapeutics beats earnings expectations but stock falls 4% By Investing.com - Investing.com South Africa
Jasper Therapeutics beats earnings expectations but stock falls 4% By Investing.com - Investing.com Australia
Jasper Therapeutics beats earnings expectations but stock falls 4% By Investing.com - Investing.com Canada
Jasper Therapeutics beats earnings expectations but stock falls 4% - Investing.com
Jasper Therapeutics beats earnings expectations but stock falls 4% By Investing.com - Investing.com India
Jasper Therapeutics beats earnings expectations but stock falls 4% - Investing.com
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
JSPR Q1 2026 Earnings: 91.94% EPS Beat Signals Cost Discipline, But Stock Slips 8.46%Earnings Season Preview - vinanet.vn
Jasper Therapeutics Q2 EPS of $(0.10) beats estimates - scanx.trade
Jasper Therapeutics (JSPR) narrows Q2 2026 loss, closes Kira deal and $132M PIPE - Stock Titan
Jasper Therapeutics Reports $2.8 Million Second-Quarter Net Loss - Quiver Quantitative
Jasper Therapeutics, Inc. (JSPR) stock: Climbs on Kira Merger and $132M Raise as Pipeline Consolidates - Blockonomi
Jasper Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln - TradingView
Jasper Therapeutics, Inc. 2Q 2026: Net loss $(2.8M), EPS $(0.10) — 10-Q Summary - TradingView
Jasper Therapeutics Reports Q2 2026 Results and Completion of Kira Pharmaceuticals Acquisition - Quiver Quantitative
JSPR Financials: Income Statement, Balance Sheet & Cash Flow | Jasper Therapeutics Inc - Stock Titan
Jasper Therapeutics (JSPR) slashes losses, acquires Kira and raises $132M - Stock Titan
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
Jasper Therapeutics Inc Stock (JSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):